Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:NAGE

Niagen Bioscience Q1 2026 Earnings Results & Report

Niagen Bioscience logo
$2.63 -0.06 (-2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$2.62 0.00 (-0.19%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Niagen Bioscience beat analyst earnings expectations in its Q1 2026 results, released May 6, 2026. The company reported EPS of $0.07 versus the $0.06 consensus estimate, while revenue was $31.47 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Niagen Bioscience EPS Results

Actual EPS
$0.07
Consensus EPS
$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Niagen Bioscience Revenue Results

Actual Revenue
$31.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Niagen Bioscience Q1 2026 Earnings FAQ

Niagen Bioscience (NASDAQ:NAGE) reported earnings of $0.07 per share for Q1 2026, beating the consensus estimate of $0.06. The report was announced on Wednesday, May 6, 2026.

Niagen Bioscience reported revenue of $31.47 million for Q1 2026.

Niagen Bioscience Earnings Headlines

Comparing Unicharm (OTCMKTS:UNICY) & Niagen Bioscience (NASDAQ:NAGE)
October 10 at 3:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105475
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle ...
October 8, 2026  |  marketscreener.comM
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation.tc pixel
October 12 at 1:00 AM  |  Paradigm Press (Ad)
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
October 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261008014757/en/andrew-shao-ph.d.-senior-vice-president-of-global-regulatory-and-scientific-affairs-at-niagen-bioscience-honored-with-the-2026-annette-dickinson-trailblazer-award-by-radicle-science-and-council-for-responsible-nutrition-crn/
Analysts Offer Insights on Consumer Goods Companies: Niagen Bioscience (NAGE) and Target (TGT)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TGT/pressreleases/4978970/analysts-offer-insights-on-consumer-goods-companies-niagen-bioscience-nage-and-target-tgt/
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261006449816/en/Niagen-Bioscience-to-Present-at-LD-Micro-20th-Annual-Main-Event/
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) is a life sciences company focused on products and technologies designed to support healthy aging and cellular health. The company’s principal technology is nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and other biological processes.

The company develops and commercializes NIAGEN-branded NR ingredients for use in dietary supplements, functional foods and beverages, and other consumer health products. Its consumer portfolio includes Tru Niagen, a direct-to-consumer supplement brand, while its ingredient business supplies NIAGEN products to manufacturers and brand partners. The company also supports its products with scientific research, quality testing and intellectual-property licensing.

Niagen Bioscience was formerly known as ChromaDex Corporation and has been associated with research and commercialization efforts involving NAD+ biology and NR. Its products are marketed through online channels, retail distribution and commercial partners in the United States and international markets. The company is led by Chief Executive Officer Rob Fried.

View Niagen Bioscience Profile
Earnings Tools